These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

94 related items for PubMed ID: 20202756

  • 1. Higher order structure of short immunostimulatory oligonucleotides studied by atomic force microscopy.
    Klein DC, Latz E, Espevik T, Stokke BT.
    Ultramicroscopy; 2010 May; 110(6):689-93. PubMed ID: 20202756
    [Abstract] [Full Text] [Related]

  • 2. Immunostimulatory CpG oligonucleotides form defined three-dimensional structures: results from an NMR study.
    He G, Patra A, Siegmund K, Peter M, Heeg K, Dalpke A, Richert C.
    ChemMedChem; 2007 Apr; 2(4):549-60. PubMed ID: 17366653
    [Abstract] [Full Text] [Related]

  • 3. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells.
    Hartmann G, Battiany J, Poeck H, Wagner M, Kerkmann M, Lubenow N, Rothenfusser S, Endres S.
    Eur J Immunol; 2003 Jun; 33(6):1633-41. PubMed ID: 12778481
    [Abstract] [Full Text] [Related]

  • 4. Towards optimal design of second-generation immunomodulatory oligonucleotides.
    Kandimalla ER, Yu D, Agrawal S.
    Curr Opin Mol Ther; 2002 Apr; 4(2):122-9. PubMed ID: 12044033
    [Abstract] [Full Text] [Related]

  • 5. CpG oligodeoxynucleotides as DNA adjuvants in vertebrates and their applications in immunotherapy.
    Chaung HC.
    Int Immunopharmacol; 2006 Oct; 6(10):1586-96. PubMed ID: 16919831
    [Abstract] [Full Text] [Related]

  • 6. Recent advances in the development of immunostimulatory oligonucleotides.
    Uhlmann E, Vollmer J.
    Curr Opin Drug Discov Devel; 2003 Mar; 6(2):204-17. PubMed ID: 12669456
    [Abstract] [Full Text] [Related]

  • 7. CpG oligonucleotides with modified termini and nicked dumbbell structure show enhanced immunostimulatory activity.
    Narayanan S, Dalpke AH, Siegmund K, Heeg K, Richert C.
    J Med Chem; 2003 Nov 06; 46(23):5031-44. PubMed ID: 14584953
    [Abstract] [Full Text] [Related]

  • 8. CpG-containing oligodeoxynucleotides induce TNF-alpha and IL-6 production but not degranulation from murine bone marrow-derived mast cells.
    Zhu FG, Marshall JS.
    J Leukoc Biol; 2001 Feb 06; 69(2):253-62. PubMed ID: 11272276
    [Abstract] [Full Text] [Related]

  • 9. DNA base pair resolution by single molecule force spectroscopy.
    Sattin BD, Pelling AE, Goh MC.
    Nucleic Acids Res; 2004 Feb 06; 32(16):4876-83. PubMed ID: 15367697
    [Abstract] [Full Text] [Related]

  • 10. CpG oligonucleotides as adjuvant in therapeutic vaccines against parasitic infections.
    Zimmermann S, Dalpke A, Heeg K.
    Int J Med Microbiol; 2008 Jan 06; 298(1-2):39-44. PubMed ID: 17716944
    [Abstract] [Full Text] [Related]

  • 11. Recent advances in immunostimulatory CpG oligonucleotides.
    Rothenfusser S, Tuma E, Wagner M, Endres S, Hartmann G.
    Curr Opin Mol Ther; 2003 Apr 06; 5(2):98-106. PubMed ID: 12772497
    [Abstract] [Full Text] [Related]

  • 12. Agonists of Toll-like receptor 9 containing synthetic dinucleotide motifs.
    Yu D, Putta MR, Bhagat L, Li Y, Zhu F, Wang D, Tang JX, Kandimalla ER, Agrawal S.
    J Med Chem; 2007 Dec 13; 50(25):6411-8. PubMed ID: 17988082
    [Abstract] [Full Text] [Related]

  • 13. The immunostimulatory activity of CpG oligonucleotides on microglial N9 cells is affected by a polyguanosine motif.
    Zhang Z, Guo K, Schluesener HJ.
    J Neuroimmunol; 2005 Apr 13; 161(1-2):68-77. PubMed ID: 15748945
    [Abstract] [Full Text] [Related]

  • 14. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides.
    Weiner GJ.
    J Leukoc Biol; 2000 Oct 13; 68(4):455-63. PubMed ID: 11037965
    [Abstract] [Full Text] [Related]

  • 15. Solution structure of the CpG containing d(CTTCGAAG)2 oligonucleotide: NMR data and energy calculations are compatible with a BI/BII equilibrium at CpG.
    Lefebvre A, Mauffret O, Lescot E, Hartmann B, Fermandjian S.
    Biochemistry; 1996 Sep 24; 35(38):12560-9. PubMed ID: 8823193
    [Abstract] [Full Text] [Related]

  • 16. Structural requirements for uptake and recognition of CpG oligonucleotides.
    Heeg K, Dalpke A, Peter M, Zimmermann S.
    Int J Med Microbiol; 2008 Jan 24; 298(1-2):33-8. PubMed ID: 17706458
    [Abstract] [Full Text] [Related]

  • 17. Immunotherapeutic utility of stimulatory and suppressive oligodeoxynucleotides.
    Ishii KJ, Gursel I, Gursel M, Klinman DM.
    Curr Opin Mol Ther; 2004 Apr 24; 6(2):166-74. PubMed ID: 15195929
    [Abstract] [Full Text] [Related]

  • 18. Novel oligodeoxynucleotide agonists of TLR9 containing N3-Me-dC or N1-Me-dG modifications.
    Putta MR, Zhu F, Li Y, Bhagat L, Cong Y, Kandimalla ER, Agrawal S.
    Nucleic Acids Res; 2006 Apr 24; 34(11):3231-8. PubMed ID: 16798912
    [Abstract] [Full Text] [Related]

  • 19. Immunomodulatory oligonucleotides containing a cytosine-phosphate-2'-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 agonists.
    Kandimalla ER, Bhagat L, Li Y, Yu D, Wang D, Cong YP, Song SS, Tang JX, Sullivan T, Agrawal S.
    Proc Natl Acad Sci U S A; 2005 May 10; 102(19):6925-30. PubMed ID: 15860583
    [Abstract] [Full Text] [Related]

  • 20. Immune mechanisms and therapeutic potential of CpG oligodeoxynucleotides.
    Wilson HL, Dar A, Napper SK, Marianela Lopez A, Babiuk LA, Mutwiri GK.
    Int Rev Immunol; 2006 May 10; 25(3-4):183-213. PubMed ID: 16818371
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.